A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients

Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:OncoTargets and therapy 2021-01, Vol.14, p.1783-1790
Hauptverfasser: Gu, Jiahui, Wang, Wantong, Wang, Shizhuo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1790
container_issue
container_start_page 1783
container_title OncoTargets and therapy
container_volume 14
creator Gu, Jiahui
Wang, Wantong
Wang, Shizhuo
description Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined. From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment. All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews. The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.
doi_str_mv 10.2147/OTT.S300523
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7955772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669417962</galeid><sourcerecordid>A669417962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</originalsourceid><addsrcrecordid>eNptkcFrHCEUh6W0NMm2p96L0EtL2a0zOupcCsuwaQuhWZrNWRx9JoaZcaIzC_nva8g2bKB4eKLf-_nkQ-hDQVZlwcS3y91udUUJqUr6Cp0WhZBLXlPy-mh_gs5SuiOEc1myt-iEUlEKWcpTpNf4D0wxpBHM5PeAG50AX02zfcDB4YLi6wmiHwBvc9nrZOZOR7wZ_XQLnQ_e4ga6Dv-GMHY69fjzdtOEXn_BWz15GKb0Dr1xukvw_lAX6Pp8s2t-Li8uf_xq1hdLwxidlgwsKw0zjAjjqopxZ6EVklmmGWfWcWkpsS3TrWtJy0VJ65I4SWpdE8kMpQv0_Sl3nNserMlvR92pMfpexwcVtFcvbwZ_q27CXom6qkTOW6BPh4AY7mdIk7oLcxzyzKqsSCGlIOSIutEdKD-4kMNM75NRa85rVoiaP1Kr_1B5Wei9CQM4n89fNHx9ajDZRYrgngcviHrUrLJmddCc6Y_Hf31m_3mlfwGH2qGL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501887002</pqid></control><display><type>article</type><title>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</title><source>Taylor &amp; Francis Open Access</source><source>Dove Press Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Gu, Jiahui ; Wang, Wantong ; Wang, Shizhuo</creator><creatorcontrib>Gu, Jiahui ; Wang, Wantong ; Wang, Shizhuo</creatorcontrib><description>Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined. From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment. All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews. The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S300523</identifier><identifier>PMID: 33727828</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Analysis ; Cancer ; Care and treatment ; Case Series ; Case studies ; Cervix ; Chemotherapy ; Diagnosis ; Disease control ; Fibroids ; Gynecology ; Health aspects ; Hysterectomy ; Immunohistochemistry ; Lymphatic system ; Medical research ; Medicine, Experimental ; Mesenchyme ; Morphology ; Pathology ; Patients ; Prognosis ; Risk groups ; Stem cells ; Surgery ; Tumors ; Uterus ; Vagina</subject><ispartof>OncoTargets and therapy, 2021-01, Vol.14, p.1783-1790</ispartof><rights>2021 Gu et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Gu et al. 2021 Gu et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</citedby><cites>FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955772/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955772/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3849,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33727828$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Jiahui</creatorcontrib><creatorcontrib>Wang, Wantong</creatorcontrib><creatorcontrib>Wang, Shizhuo</creatorcontrib><title>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined. From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment. All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews. The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.</description><subject>Analysis</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Case Series</subject><subject>Case studies</subject><subject>Cervix</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease control</subject><subject>Fibroids</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Hysterectomy</subject><subject>Immunohistochemistry</subject><subject>Lymphatic system</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mesenchyme</subject><subject>Morphology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Risk groups</subject><subject>Stem cells</subject><subject>Surgery</subject><subject>Tumors</subject><subject>Uterus</subject><subject>Vagina</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkcFrHCEUh6W0NMm2p96L0EtL2a0zOupcCsuwaQuhWZrNWRx9JoaZcaIzC_nva8g2bKB4eKLf-_nkQ-hDQVZlwcS3y91udUUJqUr6Cp0WhZBLXlPy-mh_gs5SuiOEc1myt-iEUlEKWcpTpNf4D0wxpBHM5PeAG50AX02zfcDB4YLi6wmiHwBvc9nrZOZOR7wZ_XQLnQ_e4ga6Dv-GMHY69fjzdtOEXn_BWz15GKb0Dr1xukvw_lAX6Pp8s2t-Li8uf_xq1hdLwxidlgwsKw0zjAjjqopxZ6EVklmmGWfWcWkpsS3TrWtJy0VJ65I4SWpdE8kMpQv0_Sl3nNserMlvR92pMfpexwcVtFcvbwZ_q27CXom6qkTOW6BPh4AY7mdIk7oLcxzyzKqsSCGlIOSIutEdKD-4kMNM75NRa85rVoiaP1Kr_1B5Wei9CQM4n89fNHx9ajDZRYrgngcviHrUrLJmddCc6Y_Hf31m_3mlfwGH2qGL</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Gu, Jiahui</creator><creator>Wang, Wantong</creator><creator>Wang, Shizhuo</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</title><author>Gu, Jiahui ; Wang, Wantong ; Wang, Shizhuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Case Series</topic><topic>Case studies</topic><topic>Cervix</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease control</topic><topic>Fibroids</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Hysterectomy</topic><topic>Immunohistochemistry</topic><topic>Lymphatic system</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mesenchyme</topic><topic>Morphology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Risk groups</topic><topic>Stem cells</topic><topic>Surgery</topic><topic>Tumors</topic><topic>Uterus</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Jiahui</creatorcontrib><creatorcontrib>Wang, Wantong</creatorcontrib><creatorcontrib>Wang, Shizhuo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Jiahui</au><au>Wang, Wantong</au><au>Wang, Shizhuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>1783</spage><epage>1790</epage><pages>1783-1790</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined. From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment. All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews. The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>33727828</pmid><doi>10.2147/OTT.S300523</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2021-01, Vol.14, p.1783-1790
issn 1178-6930
1178-6930
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7955772
source Taylor & Francis Open Access; Dove Press Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access
subjects Analysis
Cancer
Care and treatment
Case Series
Case studies
Cervix
Chemotherapy
Diagnosis
Disease control
Fibroids
Gynecology
Health aspects
Hysterectomy
Immunohistochemistry
Lymphatic system
Medical research
Medicine, Experimental
Mesenchyme
Morphology
Pathology
Patients
Prognosis
Risk groups
Stem cells
Surgery
Tumors
Uterus
Vagina
title A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T08%3A11%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Retrospective%20Case%20Study%20of%2013%20Uterine%20Perivascular%20Epithelioid%20Cell%20Neoplasm%20(PEComa)%20Patients&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Gu,%20Jiahui&rft.date=2021-01-01&rft.volume=14&rft.spage=1783&rft.epage=1790&rft.pages=1783-1790&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S300523&rft_dat=%3Cgale_pubme%3EA669417962%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501887002&rft_id=info:pmid/33727828&rft_galeid=A669417962&rfr_iscdi=true